Analysis – Page 96 – Goldea Capital

CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

Written by Customer Service on May 8, 2026. Posted in Earnings Releases And Operating Results.

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026 PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated first half 2026 CORE-008 Cohort CX Phase 2 first results of combination cretostimogene with gemcitabine in high-risk (HR) NMIBC BCG-exposed and BCG-unresponsive to be presented at AUA 2026 Well-positioned to deliver on key milestones with approximately $1.1 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029DALLAS, May 08, 2026 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates. “We have successfully completed non-clinical and...

Arbor Realty Trust Reports First Quarter 2026 Results and Declares Dividend of $0.17 per Share

Written by Customer Service on May 8, 2026. Posted in Earnings Releases And Operating Results.

Company Highlights:GAAP net income of $0.6 million, or $0.00 per diluted common share Distributable earnings1 of $0.07, or $0.18 per diluted common share, excluding $22.9 million of net realized losses from the resolution of certain legacy assets Declares cash dividend on common stock of $0.17 per share Servicing portfolio of ~$36.31 billion, agency loan originations of $707.6 million Structured loan portfolio of ~$12.00 billion, originations of $767.6 million and runoff of $861.0 million Closed a $762.6 million collateralized securitization vehicle with enhanced leverage, generating ~$35 million of additional liquidity Purchased $30.7 million of stock at an average price of $7.46 per share, or 66% of book valueUNIONDALE, N.Y., May 08, 2026 (GLOBE NEWSWIRE) — Arbor Realty Trust, Inc. (NYSE: ABR), today announced financial results...

Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin

Written by Customer Service on May 8, 2026. Posted in Public Companies.

Solid Intellectual Property Protection Across Four Continents Ahead of Pending Phase 3 Data Release HOUSTON, May 08, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced a significant advancement in its intellectual property portfolio with the issuance of a Hong Kong patent covering its proprietary method of reconstituting liposomal Annamycin. The newly granted patent (No. 40073244), titled “Method of Reconstituting Liposomal Annamycin,” extends protection through June 25, 2040, further reinforcing Moleculin’s long-term global exclusivity strategy. The invention is jointly owned with The University of Texas System. This patent represents an impactful layer of protection around Moleculin’s lead asset, Annamycin, at a time when the global oncology market continues to seek...

Cliq Digital AG: Acceptance period for public partial share repurchase offer has commenced

Written by Customer Service on May 8, 2026. Posted in Public Companies.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR OTHER COUNTRIES IN WHICH THE DISTRIBUTION OR PUBLICATION COULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE REFER TO THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER OF SECURITIES IN ANY JURISDICTION.Cliq Digital AG: Acceptance period for public partial share repurchase offer has commenced Düsseldorf, 8 May 2026. Cliq Digital AG (“CLIQ” or the “Company“) (ISIN DE000A35JS40) refers to its announcement of 29 April 2026 regarding the public partial share repurchase offer for up to 2,987,012 CLIQ Shares at a consideration of EUR 3.85 per share (the “Repurchase...

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Written by Customer Service on May 8, 2026. Posted in Public Companies.

TARPON SPRINGS, Fla., May 8, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that CEO Thomas Jensen has been invited to participate as a speaker at Precision Medicine Forum Europe 2026, taking place May 11–12, 2026, in Stockholm, Sweden. Presentation Details: Event: Precision Medicine Forum Europe 2026Presentation Title: Dual Inhibition of PARP and WNT: A Novel Drug-Biomarker Combination in Clinical TrialsTrack: OncologyDate: Monday, May 11, 2026Time: 10:20–10:40 CEST Mr. Jensen will discuss stenoparib’s dual mechanism of action and Allarity’s predictive biomarker, the Stenoparib DRP®, based on a 414-mRNA gene expression signature, which...

Gencor Releases Second Quarter Fiscal 2026 Results

Written by Customer Service on May 8, 2026. Posted in Earnings Releases And Operating Results.

ORLANDO, Fla., May 08, 2026 (GLOBE NEWSWIRE) — Gencor Industries, Inc. (the “Company” or “Gencor”) (NYSE American: GENC) announced today net revenue for the quarter ended March 31, 2026 was $33,799,000 compared with $38,204,000 net revenue for the quarter ended March 31, 2025. The decrease in net revenue was primarily due to lower contract equipment revenues recognized over time and associated freight revenue, which resulted from the timing of orders and shipments. As a percentage of net revenue, gross profit margins increased 200 basis points to 31.7% in the quarter ended March 31, 2026, compared to 29.7% in the quarter ended March 31, 2025. Product engineering and development expenses decreased $52,000 to $629,000 for the quarter ended March 31, 2026, as compared to $681,000 for the quarter ended March 31, 2025 primarily due to...

Alamar Biosciences Reports First Quarter 2026 Financial Results

Written by Customer Service on May 8, 2026. Posted in Earnings Releases And Operating Results.

FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported financial results for the quarter ended March 31, 2026. Recent HighlightsGenerated $26.0 million of total revenue for the first quarter of 2026, an increase of 99% as compared to the corresponding period of 2025. Launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, furthering our leadership in neurodegenerative disease research. Raised approximately $220 million in gross proceeds from our initial public offering in April 2026.“We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research...

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

Written by Customer Service on May 8, 2026. Posted in Earnings Releases And Operating Results.

– Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination – – Evorpacept data from two independent HER2-positive trials strengthens confidence in the CD47-selection hypothesis and potentially derisks path forward in HER2-positive breast cancer – – Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer is on track for topline data mid-2027 – – Phase 1 trial evaluating ALX2004 continues to enroll well, on track for safety data in 2H 2026 – – ALX strengthens leadership team with the appointment of Jeff Knight as Chief Development and...

Antelope Enterprise Holdings Limited Announces $190,000 in Realized Gains from its “Genius Plan” and Authorizes an $95,000 Share Repurchase Program, Validating its Sustainable Capital Recycling Framework

Written by Customer Service on May 8, 2026. Posted in Public Companies.

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) — Antelope Enterprise Holdings Limited (NASDAQ: AEHL, or the “Company”), today announced significant milestones in its structured digital asset allocation strategy, the “Genius Plan”. Initially launched in February 2026 as a dynamic framework to manage Bitcoin (BTC) treasury reserves, the Genius Plan has successfully transitioned into its execution validation phase, generating $190,000 in realized investment gains, as of this announcement. In direct alignment with the predefined capital recycling and return distribution mechanisms established at the plan’s inception, the Company’s Board of Directors has authorized a share repurchase program. The Company will utilize 50% of these newly realized gains – totaling $95,000 – to repurchase issued and outstanding ordinary shares in the open...

Myseum.AI to Present at 16th Annual LD Micro Invitational Conference; Picture Party Named Official Private Social Media Platform

Written by Customer Service on May 8, 2026. Posted in Public Companies.

NEW BRUNSWICK, N.J., May 08, 2026 (GLOBE NEWSWIRE) — Myseum.AI, Inc. (Nasdaq: MYSE) (“Myseum.AI” or the “Company”) a privacy-first AI and social media technology company, today announced that Chief Executive Officer Darin Myman will present at the 16th Annual LD Micro Invitational conference taking place May 17–19, 2026, in Los Angeles. Myseum.AI’s flagship next-generation instant social networking experience, Picture Party, is featured as the official private social media platform for the conference. Myman’s presentation is scheduled for Tuesday, May 19, 2026, at 11:00 a.m. PT. and will be webcast live. Management will be available for private on-on-one meetings with investors on May 18th and 19th. The presentation will focus on Picture Party, a next-gen patented instant social networking platform that enables...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals